Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well nilotinib works in treating patients with newly diagnosed chronic phase chronic myelogenous leukemia.

Key facts

Study ID

NCT00809211

Run by

Cancer Trials Ireland

People needed

40

Starts

2008-10-01

Expected to finish

2016-02-01

Last updated by the study team

2018-07-24

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
• Universitätsklinikum Charité Berlin — Berlin, Germany
• Belfast City Hospital — Belfast, Ireland
• St. James's Hospital — Dublin, Ireland
• University College Hospital — Galway, Ireland
• Chaim Sheba Medical Centre — Tel Litwinsky, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.